Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75
Published . Updated .
The average one-year price target for Fulcrum Therapeutics (NASDAQGM:FULC) has been revised to $7.75 / share. This is an increase of 11.22% from the prior estimate of $6.97 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not c
Directly affected
- FULC Fulcrum Therapeutics
Named in this report.
Indirectly affected
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Fulcrum Therapeutics (NASDAQGM:FULC) has been revised to $7.75 / share. This is an increase of 11.22% from the prior estimate of $6.97 dated September 11, 2026. These figures represent aggregate analys…
Source: Nasdaq Markets
Fulcrum Therapeutics (FULC) since this story, compared with the market
Since the first closing price after “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75,” Fulcrum Therapeutics (FULC) is -0.54%. The S&P 500 fund (SPY) is -1.08% over the same days, a +0.54% difference versus the market.
Who gains and who loses around Fulcrum Therapeutics (FULC)
Companies mentioned with this story
- FULC Fulcrum Therapeutics
Fulcrum Therapeutics (FULC) is linked, with no stored direction, high confidence in the 2 Oct 2026 story “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75.” Reason on file: The reported development directly names FULCRUM THERAPEUTICS INC in the headline; GA resolved that company to FULC
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
In “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
In “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75.” Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
In “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75,” Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
In “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
For “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75,” Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Fulcrum Therapeutics (FULC)
The 2 Oct 2026 story “Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75” names Fulcrum Therapeutics (FULC) because of this story.
For Fulcrum Therapeutics (FULC), the reason on file says The reported development directly names FULCRUM THERAPEUTICS INC in the headline; GA resolved that company to FULC
A second company, T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ), is listed for a different reason: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Fulcrum Therapeutics (FULC) price range
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99. FULC traded between 3.65 and 3.79 across 12 sessions. The latest close on file is 3.71.
A simple score for Fulcrum Therapeutics (FULC)
46 out of 100
“Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.